The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres

• Главные авторы: Teodora Spataru (Автор), Remus Popescu (Автор), Monica State (Автор), Mihai Pahomeanu (Автор), Bogdan Mateescu (Автор), Lucian Negreanu (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2024-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

During the last two decades, an increased number of molecules with multiple mechanisms of action have been approved for the treatment of inflammatory bowel disease (IBD), with a substantial increase in the costs related to therapy, which has become a concern for payers, regulators, and healthcare pr...